In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Debiopharm International SA

Division of Debiopharm Group
www.debiopharm.com

Latest From Debiopharm International SA

Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics

Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.

Financing Business Strategies

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Sanofi, Debiopharm Deals Buy ImmunoGen Extra Time

ImmunoGen has turned around two cash-generation deals in a week as it seeks to extend its funding and narrow its focus. It has sold one asset to Debiopharm and foregone future royalties on five products licensed to Sanofi in exchange for an upfront lump sum.

Deals Business Strategies

Pipeline Watch: Phase III Trials In Prostate Cancer, Diffuse Large B-cell Lymphoma

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Pipeline Watch
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Debiopharm SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Debiopharm Group
  • Senior Management
  • Bertrand Ducrey, PhD, CEO
    Chris Freitag, VP, Clin. R&D
    Alexandre Maret, Dir., Fin. & Admin.
  • Contact Info
  • Debiopharm International SA
    Phone: (41) 21 321 01 11
    Chemin Messidor 5-7
    P.O. Box 5911 Lausanne , CH-1002
    Switzerland
UsernamePublicRestriction

Register